Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: In Vitro and In Vivo Studies

doi:10.21873/anticanres.14498

CNU IR > Pharmacy and Science > Dept. of Biotechnology (including master's program) > Periodical Articles > Item 310902800/34142

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34142

Title:	Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: In Vitro and In Vivo Studies
Authors:	Chen, Hsiang Lai Gong, Jiny Yin Lin, Shih-Chao Li, Shiming Chiang, Yu-Chih Hung, Jui-Hsiang Yen, Chieh-Chi Lin, Chi-Chien
Contributors:	Tungs Taichung MetroHarbor Hosp, Div Urol, Dept Surg Natl Chung Hsing Univ, PhD Program Translat Med Natl Chung Hsing Univ, Inst Biomed Sci, IEGG & Anim Biotechnol Ctr Natl Taiwan Ocean Univ, Bachelor Degree Program Marine Biotechnol, Coll Life Sci, Virginia Polytech Inst & State Univ, Dept Biomed & Pathobiol, Blacksburg Huanggang Normal Univ, Coll Chem & Chem Engn, Hubei Key Lab Proc & Applicat Catalyt Mat Fu Jen Catholic Univ, Coll Human Ecol, Dept Restaurant Hotel & Inst Management Chia Nan Univ Pharm & Sci, Dept Biotechnol Changhua Christian Hosp, Dept Radiol, Changhua Christian Med China Med Univ Hosp, Dept Med Res Taichung Vet Gen Hosp, Dept Med Res
Keywords:	Small cell lung carcinoma Sclareol cell cycle apoptosis DNA damage xenograft
Date:	2020
Issue Date:	2022-11-18 11:25:45 (UTC+8)
Publisher:	Int Inst Anticancer Research
Abstract:	Background/Aim: This study aimed to investigate the anticancer effects and potential mechanisms of sclareol in a human small cell lung carcinoma (SCLC) cell line. Materials and Methods: Cell viability was determined by the MIT assay. Cell cycle, apoptosis and caspase activity were evaluated by flow cytometry. Cell cycle and DNA damage related protein expression was determined by western blotting. In vivo evaluation of sclareol was carried out in xenografted tumor mice models. Results: Sclareol significantly reduced cell viability, induced G(1) phase arrest and subsequently triggered apoptosis in H1688 cells. In addition, this sclareol-induced growth arrest was associated with DNA damage as indicated by phosphorylation of H2AX, activation of ATR and Chk1. Moreover, in vivo evaluation of sclareol showed that it could inhibit tumor weight and volume in a H1688 xenograft model. Conclusion: Sclareol might be a novel and effective therapeutic agent for the treatment of SCLC patients.
Relation:	Anticancer Research, v.40, n.9, pp.14
Appears in Collections:	[Dept. of Biotechnology (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	667	View/Open

Loading...